Content about AmerisourceBergen Drug Corp.

November 1, 2012

AmerisourceBergen on Thursday reported revenue dropped 0.6% to $79.5 billion for its fiscal 2012 ended Sept. 30.

VALLEY FORGE, Pa. — AmerisourceBergen on Thursday reported revenue dropped 0.6% to $79.5 billion for its fiscal 2012 ended Sept. 30. Diluted earnings per share were a record $2.76, up 10% over the prior fiscal year diluted earnings per share from continuing operations. Gross profit was up 6.7% to $2.7 billion.

January 27, 2012

AmerisourceBergen on Thursday reported $20.4 billion in revenue for the first quarter ended Dec. 31, up 2%.

VALLEY FORGE, Pa. — AmerisourceBergen on Thursday reported $20.4 billion in revenue for the first quarter ended Dec. 31, up 2%.

“We are off to a good start in our fiscal year 2012, with December quarter results in line with our expectations and excellent progress being made on the integration of our recent acquisitions,” stated Steven Collis, AmerisourceBergen president and CEO. “We continued to demonstrate expense and working capital discipline, and our balance sheet remains strong, giving us outstanding financial flexibility.”

April 4, 2011

AmerisourceBergen on Monday promoted David Neu, 53, to president of AmerisourceBergen Drug, the company's largest operating unit, effective immediately. Neu, a 29-year veteran of the company, most recently was SVP operations.

VALLEY FORGE, Pa. — AmerisourceBergen on Monday promoted David Neu, 53, to president of AmerisourceBergen Drug, the company's largest operating unit, effective immediately. Neu, a 29-year veteran of the company, most recently was SVP operations.

The role of president of AmerisourceBergen Drug previously was held by Steven Collis, currently EVP and COO. Collis recently was named to succeed David Yost as CEO upon Yost's retirement on July 1. In his new role, Neu will continue to report to Steven Collis.

October 11, 2010

Kicking off a new leadership era for its top industry trade group, pharmaceutical wholesalers elected...